Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
The Macao SAR government launches "Diesel Price Subsidy Program"

The Macao SAR government launches "Diesel Price Subsidy Program"

金十金十2026/05/07 07:04
Show original

According to Golden Ten Data on May 7, diesel is the main fuel for industrial and commercial enterprises in Macau, making it a rigidly demanded consumable for business activities, most of which are directly related to the livelihood of residents. To address this, the Macau SAR government has launched a “Diesel Price Subsidy Program” aimed at “providing short-term relief, stabilizing prices, and safeguarding livelihood,” promptly reducing cost pressures for commercial diesel users and preventing those costs from being passed on to the prices of basic goods and services. The “Diesel Price Subsidy Program” will run for two months, starting at midnight on May 11, 2026, and ending at 11:59 PM on July 10. The subsidy is targeted at local diesel users, who will receive a subsidy of 3.3 Macau Patacas per liter deducted from the purchase price at the time of payment.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

After Eli Lilly's nearly 300% surge in four years, Wall Street remains bullish: The "hidden pipeline" beyond GLP-1 is underestimated

Eli Lilly’s share price has surged nearly 300% since the approval of its first GLP-1 drug, with its market capitalization surpassing 1 trillion USD, yet Wall Street remains optimistic about its continued growth. Berenberg has upgraded Eli Lilly’s rating to “Buy," believing that Mounjaro and Zepbound will continue to see strong volume, and that the oral GLP-1 drug could further drive demand. Additionally, Eli Lilly continues to expand into areas such as cancer and sleep disorders, and the potential of its non-obesity-related pipelines remains underestimated by the market.

华尔街见闻2026/09/18 13:21